In the field of cardiovascular disease treatment, beta-blockers play a pivotal role. From 2015 to 2022, the market size of beta-blockers in China experienced continuous growth, with an annual compound growth rate of 9.87%, reaching a peak of 8.326 billion yuan in 2022. However, in 2023, affected by centralized procurement, the market size dropped to 7.835 billion yuan. In this market, 109 companies compete for 32 varieties.AstraZenecaBy virtue ofMetoprolol Succinate Extended-Release Tablets, with cumulative sales exceeding 20 billion yuan over five years;Qilu Pharmaceutical、MerckPharmaceutical companies are also showing their skills. There are significant differences in the clinical use of beta-blockers across different generations: second-generation agents are widely used, while third-generation ones are emerging. So, in this rapidly changing market, what are the competitive strategies and development trends for various companies and products? Based on the Mosearch Consulting's "Special Research Report on Beta-Blocker Market," this article analyzes the product portfolios, market performance, and competitive landscape of companies within the beta-blocker space, revealing the competitive logic and future trends in the field.

The leading company in China's β-blocker market isAstraZenecaAccording to the statistics from the Mose Pharm database, the total sales from 2019 to 2023 amounted to approximately 20.158 billion yuan, including 15.197 billion yuan in hospital sales and 4.961 billion yuan in pharmacy sales.AstraZenecaAs the only company with cumulative sales exceeding 20 billion yuan in the past five years.

In foreign pharmaceutical companies,MerckIn China, the β-blocker market also occupies an important market share, with total sales of approximately 4.294 billion yuan from 2019 to 2023, demonstrating strong market competitiveness. Among domestic pharmaceutical companies,Qilu PharmaceuticalAchieved remarkable sales performance, with total sales from 2019 to 2023 reaching approximately 4.85 billion yuan, ranking second on the corporate leaderboard.AstraZeneca、Qilu PharmaceuticalAndMerckThree companies form the first tier, while the remaining companies have smaller sales volumes, resulting in a relatively dispersed overall competitive landscape.

AstraZenecaThe main products under its umbrella areMetoprolol Succinate Extended-Release Tablets, marketed under the brand name Betaloc, is the leading variety of beta-blockers. In addition to treating hypertension, it is also widely used in the treatment of arrhythmia, heart failure, and angina pectoris, and is known as the "miracle drug" for cardiovascular and neurological medications.MerckThe main product under its flagship isBisoprolol Fumarate Tablets, the second largest variety of β-blockers, and also one of the first-choice drugs for cardiovascular diseases.Qilu PharmaceuticalThe main varieties under its umbrella areEsmolol Hydrochloride Injection, this product is the third largest variety of beta-blockers and is also a first-line drug for treating tachycardia, aortic dissection, perioperative hypertension, etc.

According to the sales database of Mose Pharm, the product with the highest sales revenue in the TOP10 hospital sales in China in 2023 isMetoprolol Succinate Extended-Release Tablets, with annual sales of approximately 2.498 billion yuan, followed byEsmolol Hydrochloride Injection(1.142 billion yuan)AndBisoprolol Fumarate Tablets(863 million yuan)The combined sales of the top ten varieties amounted to approximately 5.923 billion yuan, accounting for 75.60% of the total sales in 2023.

Currently, the most widely used β-blockers in clinical practice in China are second-generation drugs. In 2023, the market share of second-generation β-blockers was approximately 85.13%, occupying an absolute dominant position. The first generation has gradually been phased out by the market, with a market share of less than 5%. Third-generation drugs, due to their more significant efficacy and better safety, have gradually attracted market attention, and their market share exceeded 10% in 2023.

In terms of the competitive landscape of varieties, the top four varieties by market share in 2023 are as follows:Metoprolol（52.26%）、Bisoprolol（16.18%）、Esmolol（16.02%）、Arotinolol（5.78%）, the shares of various products have fluctuated slightly over the years, but overall, the order of the top four product shares has remained relatively stable.

Among β-blockers, bisoprolol was the first to enter the second round of national procurement in China.MetoprololOral conventional release formulations included in the fifth national procurement, sustained and controlled release formulations included in the seventh national procurement. After the procurement,Metoprolol/BisoprololThe combined market share decreased from 81.93% in 2019 to 68.44% in 2023.

Esmolol, Third-Generation VarietiesArotinololMarket share has rapidly increased, according to statistics from the MosaMedic Pharmaceutical Database,EsmololMarket share increased from 8.09% in 2019 to 16.02% in 2023. As of October 2024, there are 20 generic drug companies.EsmololPassed/Deemed to have passed the consistency evaluation. It has currently been selected for the tenth batch of national procurement, and the existing competitive landscape will be reshaped.

In summary, the β-blocker market in China has experienced growth and adjustments over the past few years. The centralized procurement policy has profoundly impacted the market landscape.Metoprolol、BisoprololThe market share of products such as [...] has declined, whileEsmolol、Arotinololare then presented with development opportunities.AstraZeneca、Qilu Pharmaceutical、MerckPharmaceutical companies stand out in competition with their core products. With the continuous advancement of pharmaceutical technology and the ever-changing market environment, the future β-blocker market will undoubtedly be more exciting. Third-generation drugs are expected to further expand the market with their advantages, and more pharmaceutical companies may achieve breakthroughs with innovative products or optimized strategies. Let us wait and see, and witness the next phase of development in this market together.